Business
CNS Pharmaceuticals Announces Sponsored Research Agreement with MD Anderson for Potential Cancer Treatment Technologies
HOUSTON, May 28, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the
About this update from Cns Pharmaceuticals, Inc.
[{"type":"text","content":"HOUSTON, May 28, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (\"CNS\" or the \"Company\"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, announces it has entered into a sponsored research agreement with The University of Texas MD Anderson Cancer Center relating to potential cancer treatment technologies, including WP1244, a novel DNA binding agent that is up to 500-times more potent than the clinically used chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation. \nWaldemar Priebe, M.D., Professor of Medicinal Chemistry in the Department of Experimental Therapeutics at MD Anderson, will serve as Principal Investigator for the research project. Dr. Priebe is the founder of CNS. This relationship is managed in accordance with MD Anderson's conflict of interest policies. \n\"We are delighted to be collaborating with researchers at MD Anderson to accelerate development of a novel class of antitumor agents represented by the lead compound WP1244. Most importantly, it is able to effectively cross the blood-brain barrier, thus able to kill cancer cells located in the brain. WP1244 has shown potency in killing tumor cells and in vivo activity in relevant orthotopic brain tumor model and demonstration of agent's therapeutic potential and its potentially novel mechanism of action are highly promising,\" said John M. Climaco, Chief Executive Officer of CNS. \"Dr. Priebe and his colleagues will be performing research focused on studying in detail WP1244 and this class of agents as well as on developing other unique novel technologies allowing to target CNS malignancies. We are excited by the possibility to advance new technologies such as WP1244 toward human clinical studies in patients with primary or metastatic brain cancers.\"\nAbout WP1244WP1244 is an anticancer drug candidate representing novel class of DNA binding agents with unique biological properties. Currently in preclinical studies, WP1244 is exceedingly potent with in vitro IC50 values in the subnanomolar range. A previous animal study confirmed the presence of WP1244 in murine brain tissue, thereby demonstrating its ability to cross the blood-brain barrier. WP1244 was designed, synthesized and patented at The University of Texas MD ...